6i type, targetable molecular mutations, performance status, metastatic status (de novo vs recurrent), tumor histology and baseline ER expression, are not shown. Table: 465P VariableMedian OS (months) HR (95% CI) p-valueType of post-CDK4/6i therapy ET TT 37.3 -CT * Defined according to ESO-ESMO definition Conclusions:In this international real-world cohort, second-line ET-based strategies were associated with improved overall survival compared with CT-based approaches, supporting their use after progression on CDK4/6 inhibitors.Further analyses from the ongoing data collection are ongoing.
Giraudo et al. (Fri,) studied this question.